NewAmsterdam Pharma Co N.V. (NAMS) insider trading.
In Q3 2026, insiders at NewAmsterdam Pharma Co N.V. reported 10 non-derivative transactions on 6 Forms 3, 4 and 5: 1 open-market purchase worth $227K and 5 sales worth $6.6M.
- Transactions
- 10
- Purchases (P)
- 1
- Sales (S)
- 5
- Net shares, P minus S
- -221,600
- Insiders
- 5
- Last filed
- 2026-09-15
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Kooij Louise Frederika | Officer · Chief Accounting Officer | 5 | 0 | 3 |
| Kastelein Johannes Jacob Pieter | Director, Officer · Chief Scientific Officer | 2 | 0 | 1 |
| Davidson Michael H. | Director, Officer · Chief Executive Officer | 1 | 1 | 0 |
| Smither John W | Director | 1 | 0 | 1 |
| Gunning Robert William | Officer · Vice President, Controller | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-14 | Davidson Michael H. | P (A) | 10,000 | $22.65 | 792,923 | Form 4 |
| 2026-09-04 | Smither John W | S (D) | 1,600 | $25.32 | 8,760 | Form 4 |
| 2026-09-01 | Gunning Robert William | A (A) | 3,200 | $0 | 3,200 | Form 4 |
| 2026-08-24 | Kastelein Johannes Jacob Pieter | S (D) | 125,000 | $26.91 | 69,302 | Form 4 |
| 2026-08-24 | Kastelein Johannes Jacob Pieter | M (A) | 125,000 | — | 194,302 | Form 4 |
| 2026-07-20 | Kooij Louise Frederika | S (D) | 2,915 | $31.71 | 24,353 | Form 4 |
| 2026-07-20 | Kooij Louise Frederika | S (D) | 31,885 | $31.05 | 27,268 | Form 4 |
| 2026-07-20 | Kooij Louise Frederika | S (D) | 70,200 | $29.96 | 59,153 | Form 4 |
| 2026-07-20 | Kooij Louise Frederika | M (A) | 80,000 | $11.17 | 129,353 | Form 4 |
| 2026-07-20 | Kooij Louise Frederika | M (A) | 25,000 | $11.9 | 49,353 | Form 4 |
Transaction codes in this quarter
Get NAMS insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1936258&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · NAMS company page · NewAmsterdam Pharma Co N.V. on SEC.gov
Questions
Are insiders buying or selling NewAmsterdam Pharma Co N.V. (NAMS)?
In Q3 2026, insiders at NewAmsterdam Pharma Co N.V. reported 10 non-derivative transactions on 6 Forms 3, 4 and 5: 1 open-market purchase worth $227K and 5 sales worth $6.6M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these NewAmsterdam Pharma Co N.V. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/nams.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.